Abstract

The mission of the Characterization and Formulation Core is to provide support to Projects 1, 2 and 3 by: 1) developing simple formulations; 2) performing sperm function inhibition tests; 3) evaluating their safety/toxicity potential; and 4) developing clinically advantageous formulations. Agents will be prioritized based on their in vitro antimicrobial properties (Projects 1 and 2). Simple formulations whose bases are inactive will be developed for high priority compounds and tested in animal models (Project 3). Sperm function inhibition tests will characterize the compounds as potential noncontraceptive and contraceptive antimicrobials. Based on these results as well as other considerations, the compounds will be reprioritized. Initial safety/toxicity studies will be performed with the most desirable compounds. Those which appear safe will be considered candidates for pre-IND development and clinical trial. Clinically advantageous formulations will be developed which should further increase and maximize the antimicrobial properties of the compounds. The outcome of this work will be the availability of novel, tentatively safe and potentially clinically useful active ingredients/formulations for further preclinical development.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI037940-09
Application #
6663928
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-09-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
$180,480
Indirect Cost

  Institution

Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229

  Publications

Anderson, Robert A; Feathergill, Kenneth A; Chany 2nd, Calvin J et al. (2009) Nitric oxide-dependent human acrosomal loss induced by PPCM (SAMMA) and by nitric oxide donors occurs by independent pathways: basis for synthesis of an improved contraceptive microbicide. J Androl 30:168-82
Rupp, Richard; Rosenthal, Susan L; Stanberry, Lawrence R (2005) Pediatrics and herpes simplex virus vaccines. Semin Pediatr Infect Dis 16:31-7
Bourne, Nigel; Stegall, Rachael; Montano, Raquel et al. (2005) Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother 49:1181-3
Keller, Marla J; Tuyama, Ana; Carlucci, Maria Josefina et al. (2005) Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 55:420-3
John, Minnie; Keller, Marla J; Fam, Ehsan H et al. (2005) Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 192:1731-40
Milligan, Gregg N; Young, Christal G; Meador, Michael G et al. (2005) Effects of candidate vaginally-applied microbicide compounds on innate immune cells. J Reprod Immunol 66:103-16
Anderson, Robert A; Feathergill, Kenneth; Diao, Xiao-Hui et al. (2004) Contraception by Ushercell (cellulose sulfate) in formulation: duration of effect and dose effectiveness. Contraception 70:415-22
Rupp, Richard; Stanberry, Lawrence R; Rosenthal, Susan L (2004) New biomedical approaches for sexually transmitted infection prevention: vaccines and microbicides. Adolesc Med Clin 15:393-407
Stanberry, Lawrence R; Rosenthal, Susan L; Mills, Lisa et al. (2004) Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 39:1433-8
Milligan, Gregg N; Chu, Chin-Fun; Young, Christal G et al. (2004) Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. Biol Reprod 71:1638-45

Showing the most recent 10 out of 40 publications